Bayer Challenges Nexavar Compulsory License To Natco; Says It Endangers Pharma Research
This article was originally published in PharmAsia News
Executive Summary
The German firm says challenges faced by the Indian healthcare system has little or nothing to do with patents
You may also be interested in...
Bayer And Cadila Pool Products To Form Equal Stake JV For India Market
MUMBAI - A deal that has been brewing for nearly two years has finally taken a concrete shape. Germany's Bayer Healthcare and India's Zydus Cadila have agreed to form an equal stake company that will see Bayer move its existing sales and marketing business in India to the new enterprise
Bayer Suffers Nexavar Setback As India's Supreme Court Dismisses Linkage of Patent With Generic Marketing Approval
MUMBAI - German pharma and healthcare firm Bayer suffered yet another jolt in its two-year attempt to establish a patent linkage to registration of generic versions of its kidney and liver cancer drug Nexavar (sorafenib) as India's Supreme Court dismissed the company's pleas and referred the case back to the Delhi High Court
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.